CSI: A severity index for Clostridium difficile infection at the time of admission

Journal of Hospital Infection

Volumn 79, Issue 2, 2011, Pages 151-154

  Lungulescu, O A ^a   Cao, W ^a   Gatskevich, E ^a   Tlhabano, L ^a   Stratidis, J G ^a  

^a DANBURY HOSPITAL   (United States)

Author keywords

Clostridium difficile; Colitis; Retrospective study; Severity score

Indexed keywords

ALBUMIN; CREATININE;

ABDOMINAL DISTENSION; ABDOMINAL TENDERNESS; AGED; ALBUMIN BLOOD LEVEL; ANAMNESIS; ARTICLE; ASCITES; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM DIFFICILE INFECTION SEVERITY INDEX; COLONOSCOPY; CREATININE BLOOD LEVEL; DIAGNOSTIC IMAGING; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PREDICTIVE VALUE; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 80052269831     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2011.04.017     Document Type: Article

References (32)

1. Hall I.C., O'Toole E. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe: Bacillus difficilis. Am J Dis Child 1935, 48:390-402.
2. Anonymous Antibiotics, staphylococcal enteritis and pseudomembranous enterocolitis. N Engl J Med 1953, 249:37-40.
3. Bartlett J.G. Commentary: Bartlett JG, Onderdonk AB, Cisneros RL, Kasper DL. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis 1977;136:701. J Infect Dis 2004, 190:202-209.
4. Bartlett J.G., Moon N., Chang T.W., et al. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978, 75:778-782.
5. Halsey J. Current and future treatment modalities for Clostridium difficile-associated disease. Am J Health Syst Pharm 2008, 65:705-715.
6. Barbut F., Petit J.C. Epidemiology of Clostridium difficile associated infections. Clin Microbiol Infect 2001, 7:405-410.
7. Warny M., Pepin J., Fang A., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366:1079-1084.
8. Muto C.A., Pokrywka M., Shutt K., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26:273-280.
9. Gaynes R., Rimland D., Killum E., et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004, 38:640-645.
10. McDonald L.C. Clostridium difficile: responding to a new threat from an old enemy. Infect Control Hosp Epidemiol 2005, 26:672-675.
11. McDonald L.C. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 2006, 73:187-197.
12. Hubert B., Loo V.G., Bourgault A.M., et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis 2007, 44:238-244.
13. Layton B.A., McDonald L.C., Gerding D.N., et al. Perceived increases in the incidence and severity of Clostridium difficile disease: an emerging threat that continues to unfold. Proceedings of the 15th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America 9-12 April 2005, Los Angeles, CA, USA.
14. Incidence and severity of Clostridium difficile disease: an emerging threat that continues to unfold [abstract 66]. Proceedings of the 15th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America 2005, IDSA Emerging Infections Network, Los Angeles, CA, USA.
15. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442-2449.
16. Pépin J., Valiquette L., Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. Can Med Am J 2005, 173:1037-1042.
17. Dallal R.M., Harbrecht B.G., Boujoukas A.J., et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002, 235:363-372.
18. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353:2433-2441.
19. Underwood S., Stephenson K., Fawley W.N., et al. Effects of hospital cleaning agents on spore formation by N. American and UK outbreak Clostridium difficile strains [abstr]. Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy 2005, American Society for Microbiology, Washington, DC, LB-28.
20. McMaster-Baxter N.L., Musher D.M. Clostridium difficile: recent epidemiologic findings and advances in therapy. Pharmacotherapy 2007, 27:1029-1039.
21. Gerdding D.N., Muto C.A., Owens R.C. Treatment of Clostridium difficile infection. Clin Infect Dis 2008, 46:S32-42.
22. Zar F.A., Bakkanagari S.R., Moorthi K.M.L.S.T., Davis M.B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45:302-307.
23. Teasley D.G., Gerding D.N., Olson M.M., et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhea and colitis. Lancet 1983, 2:1043-1046.
24. Thorpe C.M., Gorbach S.L. Update on Clostridium difficile. Curr Treat Options Gastroenterol 2006, 9:265-271.
25. Velazquez I., Gonzalez G., Rocha R., et al. A Severity Score Index for Clostridium difficile infection. Infect Dis Clin Pract 2008, 16:376-378.
26. Kyne L., Sougioultzis S., McFarland L.V., Kelly C.P. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 2002, 23:653-659.
27. Dubberke E.R., Wertheimer A.I. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 2009, 30:57-66.
28. Kyne L., Hamel M.B., Polavaram R., Kelly C.P. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002, 34:346-353.
29. O'Brien J.A., Lahue B.J., Caro J.J., Davidson D.M. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007, 28:1219-1227.
30. Moshkowitz M., Ben-Baruch E., Kline Z., Shimoni Z., Niven M., Konikoff F. Risk factors for severity and relapse of pseudomembranous colitis in an elderly population. Colorectal Dis 2007, 9:173-177.
31. Henrich T.J., Krakower D., Bitton A., Yakoe D.S. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 2009, 15:415-422.
32. Drew R.J., Boyle B. RUWA scoring system: a novel predictive tool for the identification of patients at high risk for complications from Clostridium difficile infection. J Hosp Infect 2009, 71:93-94.